Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 64

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 64
---
 for fertility treatments around the world.

NewGenIvf’s strategy
is to increase its international presence in Asia-Pacific countries and its international sales are subject to a number of risks, including:

| ● | increased competition as a result of more products and procedures receiving regulatory approval or otherwise free to market in international markets; |

| ● | longer accounts receivable payment cycles and difficulties in collecting accounts receivable; |

| ● | reduced or varied protection for intellectual property rights in some countries; |

| ● | export restrictions, trade regulations, and foreign tax laws; |

<div align='center'>36</div>

| ● | fluctuations in currency exchange rates; |

| ● | foreign certification and regulatory clearance or approval requirements; |

| ● | customs clearance and shipping delays; |

| ● | political, social, and economic instability abroad, terrorist attacks, and security concerns in general; |

| ● | preference for locally provided services; |

| ● | potentially adverse tax consequences, including the complexities of foreign value-added tax systems; |

| ● | the burdens of complying with a wide variety of foreign laws and different legal standards; and |

| ● | increased financial accounting and reporting burdens and complexities. |

If one or more of these risks
are realized, its business, financial condition and results of operations could be adversely affected.

Ethical, legal and social concerns related to the use of assisted reproductive technology could reduce demand for the fertility services provided by the medical facilities in NewGenIvf’s network, and thus may adversely affect the business, financial conditions and results of operations of the medical facilities in its network.

Patient sentiment and distrust
of the use of assisted reproductive technology may lead to less demand for fertility services. Assisted reproductive technologies, including
genetic testing, technologies used for surrogacy and egg donation and gender selection, have raised ethical, legal and social issues regarding
privacy and the appropriate uses of the resulting information. Government authorities could, for social or other purposes, limit or regulate
the use of assisted reproductive technology to certain conditions. Similarly, these concerns may lead patients to refuse to use, or physicians
to be reluctant to order, assisted reproductive services even if permissible. These and other ethical, legal and social concerns may limit
market acceptance of fertility services or reduce patient demand for such services, either of which could have a material adverse effect
on the business, financial condition and results of operations of the medical facilities in NewGenIvf’s network, and NewGenIvf itself.

NewGenIvf is reliant on revenue from